# Astrana Health Inc. (ASTH) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Industrials / Professional Services. Price $38.47, market value $1.9 billion.

## Valuation
- **P/E (trailing): 46.9×** (5-yr avg 39.4×, 3-yr avg 39.6×). Astrana Health Inc. trades at 46.9× trailing earnings, close to its own five-year average of 39.4×. The Industrials median in the September 2026 study was 25.7×. Forward P/E is 10.9×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 0.5×**. Each dollar of revenue is priced at 0.5×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 2.3×**. The shares trade at 2.3× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 15.4×**. Enterprise value is 15.4× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 4.9%** (5-yr avg 3.9%). Free cash flow equals 4.9% of the market value, above its five-year average of 3.9%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 2.1%**. The inverse of the P/E: 2.1% of the price is earned each year.

## Profitability
- **Operating margin: 2.6%**. 2.6% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 0.7%**. 0.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 2.9%**. 2.9% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 5.7%**. Return on all capital, debt included, is 5.7%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 1.8%**. Each dollar of assets produces 1.8% of profit.

## Growth
- **Revenue growth (1 yr): 56.4%** (3-yr 40.6%/yr, 5-yr 35.9%/yr). Revenue grew 56.4% over the last year, against 35.9% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -48.9%** (3-yr -22.5%/yr, 5-yr -14.6%/yr). Earnings per share fell 48.9%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 20.9%/yr**. Free cash flow has compounded at 20.9% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 1.33**. Debt is 1.33 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 3.7×**. It would take 3.7 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Altman Z-score: 2.73**. A Z-score of 2.73 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Astrana Health Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (8 analysts). 8 analysts cover Astrana Health Inc.; the consensus is strong_buy, with an average price target of $51.50 (+34% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 24.8%** (YTD 55.1%, 3-mo 1.3%). The shares are up 24.8% over twelve months including dividends.
- **From 52-week high: -25.4%** (112.8% above the low). Trading 25% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 0.79** (volatility 67%). Beta of 0.79 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ASTH · Page: https://foliofundamentals.com/stocks/asth

Not investment advice.